Exploring the Hippo Pathway as a Target for Gastric Cancer Treatment

Overview of Gastric Cancer

A recent review published in *Cancer Letters* examines the Hippo pathway as a potential therapeutic target for gastric cancer. This form of cancer arises in the stomach lining, where malignant cells can develop tumors. Gastric cancer ranks among the most prevalent cancers globally and has one of the highest mortality rates. This is largely due to late-stage diagnoses, as early symptoms are often subtle or mistaken for less serious health issues.

Risk Factors and Treatment Options

Several risk factors contribute to gastric cancer, including age, diet, preexisting stomach conditions, and infection by the bacterium H. pylori. Treatment options vary based on the disease’s stage and typically involve surgery, systemic chemotherapy, or abdominal radiotherapy. However, in advanced cases where surgery is not feasible, chemotherapy—with or without targeted antibodies—often fails to cure the disease, only extending patient survival by a few months. This highlights the urgent need for innovative treatment strategies.

Challenges in Targeting Signaling Pathways

Recent Discoveries in Molecular Mechanisms

Advancements in genome sequencing have illuminated the complex molecular mechanisms driving gastric cancer. Numerous genetic mutations affecting critical signaling pathways related to cellular functions, such as DNA repair and growth, have been identified. While targeting these pathways presents potential treatment avenues, it poses significant challenges.

Limitations of Current Approaches

The diversity of mutations complicates the targeting of a single pathway effectively. Moreover, some strategies that focus on pivotal pathways essential for survival may inadvertently exacerbate patient conditions rather than improve them.

The Role of the Hippo Pathway in Gastric Cancer

Significance of the Hippo Pathway

Researchers have identified the Hippo pathway as a crucial element in tumor progression. This signaling pathway regulates organ size, tissue function, and is notably disrupted in gastric cancer, playing a role in multiple stages of malignancy.

Insights from Recent Research

A comprehensive review from Zhejiang University in China explores the biochemistry of the Hippo pathway in gastric cancer. The authors discuss various strategies for leveraging the Hippo pathway as a therapeutic target, highlighting several promising approaches.

Potential Therapeutic Approaches Targeting the Hippo Pathway

Small Molecule Drugs

Two proteins central to the Hippo pathway, YAP and TAZ, have been recognized as potential drug targets. Both proteins are overexpressed in cancer cells compared to healthy tissue. Screening nearly 3,000 small molecules has identified verteporfin, which disrupts a significant interaction contributing to cancer progression. However, its original design for another use and photosensitivity limit its clinical applicability, prompting ongoing searches for more suitable molecules.

RNA Therapy

RNA plays a vital role in translating genetic information into proteins. Introducing complementary RNA strands can inhibit the translation process, thereby reducing YAP and TAZ levels. Experiments involving mice with gastric cancer have shown reduced tumor sizes due to this intervention. Nonetheless, concerns regarding off-target effects and the associated risks of RNA therapy remain.

Peptide-Based Approaches

Peptides, which are short chains of amino acids, have demonstrated potential in combating gastric cancer in laboratory settings. They can bind to critical proteins within the signaling cascade that drives tumor growth. However, challenges such as limited cell membrane permeability and degradation by cellular mechanisms hinder their clinical effectiveness. Enhancements in peptide stability and permeability through molecular modifications may improve this treatment strategy.

Conclusion

The molecular processes underlying gastric cancer are intricate, presenting challenges for understanding and treatment. Developing better genetic models that accurately replicate the effects of a disrupted Hippo pathway in gastric cells is essential for further exploration. Significant work remains to create clinically validated pharmaceutical strategies targeting the Hippo pathway in gastric cancer.

Written by Adriano Vissa, PhD
Reference: Qiao Y, Li T, Zheng S, and Wang H. The Hippo Pathway as a drug target in gastric cancer. *Cancer Letters*. 420 (2018) 14-25.